192775-41-0Relevant academic research and scientific papers
Pyrido[2,3-d]pyrimidin-5-ones: A novel class of antiinflammatory macrophage colony-stimulating factor-1 receptor inhibitors
Huang, Hui,Hutta, Daniel A.,Rinker, James M.,Hu, Aping,Parsons, William H.,Schubert, Carsten,Desjarlais, Renee L.,Crysler, Carl S.,Chaikin, Margery A.,Donatelli, Robert R.,Chen, Yanmin,Cheng, Deping,Zhou, Zhao,Yurkow, Edward,Manthey, Carl L.,Player, Mark R.
experimental part, p. 1081 - 1099 (2010/01/07)
A series of pyrido[2,3-d]pyrimidin-5-ones has been synthesized and evaluated as inhibitors of the kinase domain of macrophage colony-stimulating factor-1 receptor (FMS). FMS inhibitors may be useful in treating rheumatoid arthritis and other chronic infla
Pd/C-Mediated synthesis of indoles in water
Layek, Mohosin,Lakshmi, Udaya,Kalita, Dipak,Barange, Deepak K.,Islam, Aminul,Mukkanti, K.,Pal, Manojit
experimental part, (2010/04/22)
We describe the utility of a Pd/C-Cu mediated method in the synthesis of 2,s 5-disubstituted indoles in water via a coupling-cyclization strategy. Further application of this methodology has been demonstrated in the preparation of a target indole derivative via a 7-step process the key step being the Pd/C-mediated coupling reaction.
5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE
-
Page/Page column 98, (2008/12/05)
The invention addresses the current need for selective and potent protein tyrosine kinase inhibitors by providing potent inhibitors of c-fms kinase. The invention is directed to the novel compounds of Formula I: or a salt, stereoisomer, tautomer, crystalline, polymorph, amorphous, solvate, hydrate, ester, prodrug or metabolite form thereof, wherein A, Y, Z, R101 and R200 are described in the specification.
INHIBITORS OF C-FMS KINASE
-
Page/Page column 51, (2008/06/13)
The invention is directed to compounds of Formula I: wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, colon cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including arthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.
PROCESS FOR PREPARING NARATRIPTAN HYDROCHLORIDE
-
Page/Page column 16, (2010/02/15)
A process for preparing naratriptan hydrochloride, N-methyl-3-(1-methyl-4-piperidinyl)-1H-indole-5-ethanesulphonamide hydrochloride having formula (I).
Synthesis and evaluation of potent and selective β3 adrenergic receptor agonists containing acylsulfonamide, sulfonylsulfonamide, and sulfonylurea carboxylic acid isosteres
Uehling, David E.,Donaldson, Kelly H.,Deaton, David N.,Hyman, Clifton E.,Sugg, Elizabeth E.,Barrett, David G.,Hughes, Robert G.,Reitter, Barbara,Adkison, Kim K.,Lancaster, Mary E.,Lee, Frank,Hart, Robert,Paulik, Mark A.,Sherman, Bryan W.,True, Timothy,Cowan, Conrad
, p. 567 - 583 (2007/10/03)
Starting from phenethanolamine aniline leads 3a and 3b, we have identified a series of functionally potent and selective β3 adrenergic receptor (AR) agonists containing acylsulfonamide, sulfonylsulfonamide, or sulfonylurea groups within the ani
